Filter your results
- 4
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 4
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react.British Journal of Haematology, 2015, 169 (2), pp.249-261. ⟨10.1111/bjh.13272⟩
Journal articles
hal-01120630v1
|
|||
|
Childhood Hodgkin's lymphoma, non-Hodgkin's lymphoma and factors related to the immune system: the Escale Study (SFCE).International Journal of Cancer, 2011, 129 (9), pp.2236-47. ⟨10.1002/ijc.25862⟩
Journal articles
hal-01120675v1
|
||
|
Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 ProtocolsPediatric Blood and Cancer, 2016, 63 (7), pp.1214-1221. ⟨10.1002/pbc.25990⟩
Journal articles
hal-01299290v1
|
||
|
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocolBritish Journal of Haematology, 2014, 165 (3), pp.392--401. ⟨10.1111/bjh.12749⟩
Journal articles
hal-01064611v1
|